A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate High or Very High Risk Myelodysplastic Syndrome (MDS).

  • STATUS
    Not Recruiting
  • End date
    Aug 14, 2023
  • participants needed
    120
  • sponsor
    Novartis Pharmaceuticals
Updated on 23 June 2021
Investigator
Novartis Pharmaceuticals
Primary Contact
Highlands Oncology Group (1.2 mi away) Contact
+71 other location
decitabine
cell transplantation
bone marrow procedure
azacitidine
high risk myelodysplastic syndrome

Summary

This Phase II is a multicenter, randomized, two-arm parallel-group, double-blind, placebo-controlled study of MBG453 or placebo added to hypomethylating agents (azacitidine or decitabine) in adult subjects with IPSS-R intermediate, high or very high risk myelodysplastic syndrome (MDS) not eligible for Hematopoietic Stem Cell Transplant (HSCT) or intensive chemotherapy.

Details
Condition Bone marrow disorder, Preleukemia, MYELODYSPLASTIC SYNDROME, Myelodysplastic Syndromes (MDS)
Treatment Placebo, MBG453, Hypomethylating agents
Clinical Study IdentifierNCT03946670
SponsorNovartis Pharmaceuticals
Last Modified on23 June 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note